SWTX logo

SpringWorks Therapeutics (SWTX) Cash from financing

annual CFF:

$4.76M-$291.88M(-98.39%)
December 31, 2024

Summary

  • As of today (July 1, 2025), SWTX annual cash flow from financing activities is $4.76 million, with the most recent change of -$291.88 million (-98.39%) on December 31, 2024.
  • During the last 3 years, SWTX annual CFF has risen by +$3.61 million (+311.67%).
  • SWTX annual CFF is now -98.60% below its all-time high of $340.70 million, reached on December 31, 2022.

Performance

SWTX Cash from financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSWTXcash flow metrics

quarterly CFF:

-$10.61M-$11.26M(-1724.66%)
March 31, 2025

Summary

  • As of today (July 1, 2025), SWTX quarterly cash flow from financing activities is -$10.61 million, with the most recent change of -$11.26 million (-1724.66%) on March 31, 2025.
  • Over the past year, SWTX quarterly CFF has dropped by -$10.06 million (-1821.92%).
  • SWTX quarterly CFF is now -103.12% below its all-time high of $340.23 million, reached on September 30, 2022.

Performance

SWTX quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSWTXcash flow metrics

TTM CFF:

-$5.29M-$10.06M(-211.15%)
March 31, 2025

Summary

  • As of today (July 1, 2025), SWTX TTM cash flow from financing activities is -$5.29 million, with the most recent change of -$10.06 million (-211.15%) on March 31, 2025.
  • Over the past year, SWTX TTM CFF has dropped by -$303.23 million (-101.78%).
  • SWTX TTM CFF is now -101.55% below its all-time high of $340.70 million, reached on December 31, 2022.

Performance

SWTX TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSWTXcash flow metrics

Cash from financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

SWTX Cash from financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-98.4%-1821.9%-101.8%
3 y3 years+311.7%-4164.8%-599.9%
5 y5 years-98.6%-10000.0%-103.1%

SWTX Cash from financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-98.6%+311.7%-103.1%at low-101.5%at low
5 y5-year-98.6%+311.7%-103.1%at low-101.5%at low
alltimeall time-98.6%+311.7%-103.1%at low-101.5%at low

SWTX Cash from financing History

DateAnnualQuarterlyTTM
Mar 2025
-
-$10.61M(-1724.7%)
-$5.29M(-211.1%)
Dec 2024
$4.76M(-98.4%)
$653.00K(-49.4%)
$4.76M(-98.4%)
Sep 2024
-
$1.29M(-61.7%)
$303.18M(+0.5%)
Jun 2024
-
$3.37M(-710.7%)
$301.65M(+1.2%)
Mar 2024
-
-$552.00K(-100.2%)
$297.94M(+0.4%)
Dec 2023
$296.64M(-12.9%)
$299.07M(<-9900.0%)
$296.64M(<-9900.0%)
Sep 2023
-
-$242.00K(-29.2%)
-$2.13M(-100.6%)
Jun 2023
-
-$342.00K(-81.5%)
$338.34M(-0.1%)
Mar 2023
-
-$1.85M(-720.1%)
$338.59M(-0.6%)
Dec 2022
$340.70M(>+9900.0%)
$298.00K(-99.9%)
$340.70M(+0.0%)
Sep 2022
-
$340.23M(<-9900.0%)
$340.65M(>+9900.0%)
Jun 2022
-
-$88.00K(-133.7%)
$842.00K(-20.5%)
Mar 2022
-
$261.00K(+7.0%)
$1.06M(-8.5%)
DateAnnualQuarterlyTTM
Dec 2021
$1.16M(-99.6%)
$244.00K(-42.6%)
$1.16M(-99.6%)
Sep 2021
-
$425.00K(+229.5%)
$270.89M(-0.0%)
Jun 2021
-
$129.00K(-64.1%)
$270.89M(+0.0%)
Mar 2021
-
$359.00K(-99.9%)
$270.84M(+0.1%)
Dec 2020
$270.49M(-18.9%)
$269.97M(>+9900.0%)
$270.49M(>+9900.0%)
Sep 2020
-
$428.00K(+448.7%)
$532.00K(-99.7%)
Jun 2020
-
$78.00K(+1200.0%)
$169.84M(+0.0%)
Mar 2020
-
$6000.00(-70.0%)
$169.76M(-49.1%)
Dec 2019
$333.71M(+562.4%)
$20.00K(-100.0%)
$333.71M(+0.0%)
Sep 2019
-
$169.73M(>+9900.0%)
$333.69M(+103.5%)
Jun 2019
-
$0.00(-100.0%)
$163.96M(0.0%)
Mar 2019
-
$163.96M
$163.96M
Dec 2018
$50.38M
-
-

FAQ

  • What is SpringWorks Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for SpringWorks Therapeutics?
  • What is SpringWorks Therapeutics annual CFF year-on-year change?
  • What is SpringWorks Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for SpringWorks Therapeutics?
  • What is SpringWorks Therapeutics quarterly CFF year-on-year change?
  • What is SpringWorks Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for SpringWorks Therapeutics?
  • What is SpringWorks Therapeutics TTM CFF year-on-year change?

What is SpringWorks Therapeutics annual cash flow from financing activities?

The current annual CFF of SWTX is $4.76M

What is the all time high annual CFF for SpringWorks Therapeutics?

SpringWorks Therapeutics all-time high annual cash flow from financing activities is $340.70M

What is SpringWorks Therapeutics annual CFF year-on-year change?

Over the past year, SWTX annual cash flow from financing activities has changed by -$291.88M (-98.39%)

What is SpringWorks Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of SWTX is -$10.61M

What is the all time high quarterly CFF for SpringWorks Therapeutics?

SpringWorks Therapeutics all-time high quarterly cash flow from financing activities is $340.23M

What is SpringWorks Therapeutics quarterly CFF year-on-year change?

Over the past year, SWTX quarterly cash flow from financing activities has changed by -$10.06M (-1821.92%)

What is SpringWorks Therapeutics TTM cash flow from financing activities?

The current TTM CFF of SWTX is -$5.29M

What is the all time high TTM CFF for SpringWorks Therapeutics?

SpringWorks Therapeutics all-time high TTM cash flow from financing activities is $340.70M

What is SpringWorks Therapeutics TTM CFF year-on-year change?

Over the past year, SWTX TTM cash flow from financing activities has changed by -$303.23M (-101.78%)
On this page